Clinical trials: End-stage Kidney Disease
End Stage Renal Disease, Peritoneal Dialysis
Chlorhexidine Gluconate Versus Mupirocin Ointment in the Prevention of Peritoneal Dialysis-Related Infection
This pilot study aims to evaluate effectiveness, safety, and cost-utility of chlorhexidine gluconate (CHG)-soaked cloths compares to mupirocin ointment and exit site usual care (normal saline) with aseptic technique in prevention…
- Trial name
- COSMO-PD (NCT02547103)
- Testing
- Chlorhexidine gluconate-soaked cloths, Normal saline, mupirocin ointment
- Where
- Thailand
- Volunteers
- 354 people
- Sponsor
- Chiang Mai University
End Stage Renal Disease (ESRD), Diabetes
Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients
Primary Objective: To demonstrate that use of glucose sparing prescriptions, Dianeal, Extraneal, Nutrineal (D-E-N) versus Dianeal only, in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD) patients…
- Conditions
- End Stage Renal Disease (ESRD), Diabetes, CAPD
- Trial name
- EDEN (NCT01219959)
- Testing
- Dianeal, Dianeal, Extraneal, Nutrineal
- Where
- 16 sites in Colombia
- Volunteers
- 71 people
- Sponsor
- Vantive Health LLC
End Stage Renal Disease
Accelerated Mortality on Renal Replacement
The purpose of this study is to prospectively identify blood markers that identify chronic hemodialysis patients at risk for early (<90 days) and late (>= 1 year) mortality
- Trial name
- ArMORR (NCT00505180)
- Volunteers
- 10,018 people
- Sponsor
- Massachusetts General Hospital
Oxidative Stress, Inflammation
CoQ10 Biomarker Trial
The investigators believe that relieving the oxidative stress experienced by hemodialysis patients may help improve cardiovascular health.
- Conditions
- Oxidative Stress, Inflammation, Endothelial Dysfunction
- Trial name
- NCT01408680
- Testing
- Coenzyme Q10
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Washington
End-Stage Renal Disease, Inflammation
Channa Striatus Extract on Albumin and Hs-CRP ESRD
This study is a randomised, double blind, placebo-controlled study in patients with ESRD on HD or CAPD based RRTs at Moewardi General Hospital in Surakarta, Indonesia from January to March 2021.
- Trial name
- NCT05614362
- Testing
- Channa Striatus extract, Maltodextrin
- Where
- Indonesia
- Volunteers
- 40 people
- Sponsor
- Universitas Sebelas Maret
Chronic Renal Failure, Glomerular Disease
TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)
In Chronic Renal Failure (CRF) patients with primary glomerular disease or nephrosclerosis as the primary disease: To confirm the superiority of TRK-100STP over placebo To determine the recommended therapeutic dose in the 2 doses…
- Conditions
- Chronic Renal Failure, Glomerular Disease, Nephrosclerosis
- Trial name
- NCT01090037
- Testing
- TRK-100STP high dose, TRK-100STP low dose
- Where
- 7 sites in China, Hong Kong and 5 more
- Volunteers
- 892 people
- Sponsor
- Toray Industries, Inc
End Stage Renal Disease, Hyperphosphatemia
A Study of Ferric Citrate to Improve Inflammation and Lipid Levels
The risk of cardiovascular mortality in patients with end stage renal disease on hemodialysis is 10-100 times higher than the normal population.
- Conditions
- End Stage Renal Disease, Hyperphosphatemia, Chronic Inflammation
- Trial name
- NCT02661295
- Testing
- Ferric Citrate
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Winthrop University Hospital
Hemodialysis, Chronic Renal Failure
Erythropoietin Therapy in Patients With Chronic Renal Failure: A Study of Time Dependent Activity
The purpose of this research study was to determine if the activity of erythropoietin (r-HuEPO) is time dependent when given to chronic renal failure patients at three different times of day.
- Conditions
- Hemodialysis, Chronic Renal Failure, Anemia
- Trial name
- NCT00744445
- Testing
- r-HuEPO
- Volunteers
- 46 people
- Sponsor
- Sunnybrook Health Sciences Centre
Venous Stenosis, Venous Occlusion
The Solaris DE Sirolimus-Eluting Covered Stent for the Treatment of AV Access Stenosis or Occlusion
The goal of this clinical trial is to demonstrate the safety and efficacy of Solaris Drug-Eluting Covered Stent (Solaris DE) in the treatment of stenosis or occlusion within the outflow circuit of the dialysis access including…
- Conditions
- Venous Stenosis, Venous Occlusion, Chronic Renal Failure
- Trial name
- DEScover (NCT06096142)
- Testing
- Solaris DE, PTA, Solaris DE (200)
- Where
- 5 sites in Brazil
- Volunteers
- 160 people
- Sponsor
- Scitech Produtos Medicos SA
Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2
The Life Style Patterns and the Development Trend of Chronic Diseases in Healthy and Sub-healthy Groups Were Analyzed by Using Data-mining Techniques
Used multi-year health examination member profile by multi-algorithms technology, to find comprehensive key hazard factors or important high-risk group components for metabolic syndrome and chronic kidney disease or more common…
- Conditions
- Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4
- Trial name
- NCT05225454
- Where
- Taiwan
- Volunteers
- 81,108 people
- Sponsor
- Far Eastern Memorial Hospital
End Stage Renal Disease
Generic Tacrolimus in the Elderly - Prograf® vs Tacni®
Test bioequivalence of generic tacrolimus (Tacni), using original tacrolimus (Prograf) as comparator, in elderly (>60 yr) renal transplant recipients
- Trial name
- GenTac (NCT01698541)
- Testing
- Tacrolimus
- Where
- Norway
- Volunteers
- 28 people
- Sponsor
- University of Oslo School of Pharmacy
Renal Impairment, End-stage Renal Disease
An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.
The purpose of this study is to evaluate the percentage of participants with sustained virologic response 12 weeks after the actual end of study treatment (SVR12)
- Trial name
- NCT02397395
- Testing
- Simeprevir (SMV) 150 mg, Daclatasvir (DCV) 60 mg
- Where
- 6 sites in France, Spain
- Sponsor
- Janssen R&D Ireland
Chronic Hepatitis C, End Stage Renal Disease
A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)
1. A maximally tolerated dose of ribavirin can be defined in each patient with ESRD undergoing hemodialysis. 2. Patients with Chronic Hepatitis C Virus (HCV)and End-Stage Renal Disease (ESRD)undergoing hemodialysis will be able…
- Trial name
- NCT01731301
- Testing
- Ribavirin, Peginterferon, Boceprevir
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Liver Institute of Virginia
End Stage Renal Disease on Dialysis, Hemodialysis Complication
Virtual Reality Intradialysis: Last vs. First Part of the Session
The main objective of this investigation is to assess if an intradialysis virtual reality exercise program during the last two hours of the hemodialysis session results in greater hemodynamic stability than exercise performed…
- Trial name
- VRI (NCT04046042)
- Testing
- Conventional exercise, Exercise during the last two hours of the hemodialysis session
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Cardenal Herrera University
End Stage Renal Disease
Use of Ointments in Prevention of Catheter Related Infections in PD
Peritoneal dialysis (PD) is used for the treatment of end-stage renal disease in approximately 25% of patients requiring dialysis in Canada. The most common complication is bacterial infection or 'peritonitis'.
- Trial name
- NCT00400595
- Testing
- Mupirocin ointment, Polysporin Triple
- Where
- 2 sites in Canada
- Volunteers
- 200 people
- Sponsor
- University Health Network, Toronto
Supportive Care, Exercise Adaptations
Intradialytic Exercise and Cognitive Function
Exercise training may improve global and domain-specific cognitive function, mental health, psychological well-being, dialysis efficacy, and health-related quality of life in people with end-stage kidney disease receiving…
- Conditions
- Supportive Care, Exercise Adaptations, Exercise Training Therapy, Clinical Exercise
- Trial name
- EXCOG-HD (NCT07780175)
- Testing
- Resistance Training, Aerobic training, Combination Training
- Where
- Cyprus
- Volunteers
- 60 people
- Sponsor
- University of Thessaly
Cardiovascular Diseases, Cardiovascular Abnormalities
Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
The primary objective is to assess the effect of 2 dose levels of SNF472 (300 mg and 600 mg) compared to placebo on the progression of coronary artery calcium volume score over a 12-month (52 weeks) period in ESRD patients on HD
- Conditions
- Cardiovascular Diseases, Cardiovascular Abnormalities, Calcifications, Vascular, Endstage Renal Disease
- Trial name
- NCT02966028
- Testing
- SNF472
- Where
- 75 sites in United States, Spain and 1 more
- Volunteers
- 274 people
- Sponsor
- Sanifit Therapeutics S. A.
End-stage Renal Failure
The ONE Study UK Treg Trial
A study to assess cell therapy as a treatment to prevent kidney transplant rejection. The trial will involve purification of naturally occurring regulatory T cells (nTregs) from living-donor renal transplant recipients.
- Trial name
- ONETreg1 (NCT02129881)
- Testing
- Autologous regulatory T Cell Product
- Where
- 2 sites in United Kingdom
- Volunteers
- 15 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Sevoflurane, Kidney Diseases
Comparing Sevoflurane With Propofol Sedation in ESRF Patients
End-stage renal failure (ESRF) cohorts undergo brachiocephalic fistula(BCF) transposition with supraclavicular block. However, this is inadequate because the incision may extend to the axillary region which requires…
- Conditions
- Sevoflurane, Kidney Diseases, Procedural Hypotension
- Trial name
- NCT04839536
- Testing
- Sevoflurane inhalant product
- Volunteers
- 36 people
- Sponsor
- University of Malaya
End Stage Renal Disease, Hemodialysis Vascular Access Failure
Reduction of Plasma Free VEGF-A Using Low-dose Bevacizumab in Hemodialysis Patients
The primary purpose of this pilot study is to assess the pharmacokinetic profile of low-dose bevacizumab and its effectiveness in reducing plasma free VEGF-A levels safely in hemodialysis patients.
- Trial name
- NCT02695641
- Testing
- 1.25mg bevacizumab, 2.50mg bevacizumab
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.